Literature DB >> 19733542

Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis.

Stanley J Tamaki1, Yakop Jacobs, Monika Dohse, Alexandra Capela, Jonathan D Cooper, Michael Reitsma, Dongping He, Robert Tushinski, Pavel V Belichenko, Ahmad Salehi, William Mobley, Fred H Gage, Stephen Huhn, Ann S Tsukamoto, Irving L Weissman, Nobuko Uchida.   

Abstract

Infantile neuronal ceroid lipofuscinosis (INCL) is a fatal neurodegenerative disease caused by a deficiency in the lysosomal enzyme palmitoyl protein thioesterase-1 (PPT1). Ppt1 knockout mice display hallmarks of INCL and mimic the human pathology: accumulation of lipofuscin, degeneration of CNS neurons, and a shortened life span. Purified non-genetically modified human CNS stem cells, grown as neurospheres (hCNS-SCns), were transplanted into the brains of immunodeficient Ppt1(-/)(-) mice where they engrafted robustly, migrated extensively, and produced sufficient levels of PPT1 to alter host neuropathology. Grafted mice displayed reduced autofluorescent lipofuscin, significant neuroprotection of host hippocampal and cortical neurons, and delayed loss of motor coordination. Early intervention with cellular transplants of hCNS-SCns into the brains of INCL patients may supply a continuous and long-lasting source of the missing PPT1 and provide some therapeutic benefit through protection of endogenous neurons. These data provide the experimental basis for human clinical trials with these banked hCNS-SCns.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733542     DOI: 10.1016/j.stem.2009.05.022

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  57 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

Review 2.  Stem cells as a potential therapy for epilepsy.

Authors:  Steven N Roper; Dennis A Steindler
Journal:  Exp Neurol       Date:  2012-01-13       Impact factor: 5.330

3.  Prospects for stem cell therapy in neuronal ceroid lipofuscinosis.

Authors:  Michael C Kruer; David A Pearce; Paul J Orchard; Robert D Steiner
Journal:  Regen Med       Date:  2013-09       Impact factor: 3.806

4.  Immunohistochemical toolkit for tracking and quantifying xenotransplanted human stem cells.

Authors:  Justine Allard; Ké Li; Xavier Moles Lopez; Stéphane Blanchard; Paul Barbot; Sandrine Rorive; Christine Decaestecker; Roland Pochet; Delphine Bohl; Angelo C Lepore; Isabelle Salmon; Charles Nicaise
Journal:  Regen Med       Date:  2014       Impact factor: 3.806

5.  Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.

Authors:  Marie S Roberts; Shannon L Macauley; Andrew M Wong; Denis Yilmas; Sarah Hohm; Jonathan D Cooper; Mark S Sands
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

6.  Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).

Authors:  Mark S Sands
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

7.  Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis.

Authors:  Shannon L Macauley; Marie S Roberts; Andrew M Wong; Francesca McSloy; Adarsh S Reddy; Jonathan D Cooper; Mark S Sands
Journal:  Ann Neurol       Date:  2012-02-24       Impact factor: 10.422

Review 8.  Fetal stem cell transplantation: Past, present, and future.

Authors:  Tetsuya Ishii; Koji Eto
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

9.  A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs.

Authors:  Natalie A Villani; Garrett Bullock; Jennifer R Michaels; Osamu Yamato; Dennis P O'Brien; Tendai Mhlanga-Mutangadura; Gary S Johnson; Martin L Katz
Journal:  Mol Genet Metab       Date:  2019-04-17       Impact factor: 4.797

10.  Delivering drugs to the central nervous system: an overview.

Authors:  Patricia I Dickson
Journal:  Drug Deliv Transl Res       Date:  2012-06       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.